Click a topic below for an index of articles:

 

New-Material

Home

Alternative-Treatments

Financial or Socio-Economic Issues

Forum

Health Insurance

Hepatitis

HIV/AIDS

Institutional Issues

International Reports

Legal Concerns

Math Models or Methods to Predict Trends

Medical Issues

Our Sponsors

Occupational Concerns

Our Board

Religion and infectious diseases

State Governments

Stigma or Discrimination Issues

If you would like to submit an article to this website, email us at info@heart-intl.net for a review of this paper
info@heart-intl.net

 

any words all words
Results per page:

“The only thing necessary for these diseases to the triumph is for good people and governments to do nothing.”

       

Statistics and meaning of normal ALTs with Hepatitis C Virus+....
(WebMD), 8/28/01 7:31 p.m.

This article contains discussion of several published studies which look at Hepatitis C Virus positive individuals with normal ALTs (liver function test) and the relationship between ALT levels and Hepatitis C Virus disease progression. Whether or not such individuals should initiate Hepatitis C Virus treatment is discussed.

Natural History of Hepatitis C Virus Carriers With Persistently Normal Aminotransferase Levels

Persico M, Persico E, Rosalba S, Conte S, De Seta M, Coppola L, Palmienteri B, Sasso FC, and Torella R Internal Medicine and Hepatology Unit, II University of Naples, Naples, Italy GASTROENTEROLOGY 2000;118:760-764

Abstract

Background & Aims:

Some patients with serum hepatitis C virus (Hepatitis C Virus) have persistently normal aminotransferase (ALT) levels and are affected by cirrhosis. This study prospectively evaluated progression of the disease in a group of anti-Hepatitis C Virus-positive patients with persistently normal ALT levels.

Methods:

Thirty-seven subjects were studied. Each subject underwent liver biopsy at baseline and after 5 years of follow-up. At baseline, serum samples were tested for genotypes and Hepatitis C Virus RNA load. ALT levels and serum Hepatitis C Virus RNA were tested every other month and every 6 months, respectively. Patients with increased ALT were discharged from the study and treated with IFN. Five years after the end of IFN therapy, a liver biopsy was performed.

Results:

Liver biopsy at baseline showed chronic hepatitis in 34 patients and normal histology in 3 patients, 2 of whom were negative for Hepatitis C Virus RNA and 1 positive. Hepatitis C Virus genotypes were distributed as follows: 2a, 56%; 1b, 41%; and 1a, 3%. At the end of 7-year follow-up, 73% of the patients still had normal ALT values. Liver histology after 5 years was comparable to that observed at entry to study.

    

Conclusions:

Most patients with persistently normal ALT serum levels have very mild chronic hepatitis. However, healthy anti-Hepatitis C Virus-positive subjects exist. In patients with Hepatitis C Virus-related chronic hepatitis associated with persistently normal ALT levels, the grade of disease activity does not increase over years and progression to cirrhosis is slow or absent.

Introduction:

Many subjects with hepatitis C virus (Hepatitis C Virus) infection have persistently normal aminotransferase (ALT) levels and are considered asymptomatic anti-Hepatitis C Virus carriers. Most of these patients have been documented to have some degree of histologically proven chronic liver damage ranging from mild chronic hepatitis to liver cirrhosis (6). Hepatitis C Virus genotype distribution and viral load have also been explored, and available data in literature are still conflicting.

Several studies suggest that these patients do not benefit from interferon treatment. However, no data are available on the natural history of chronic hepatitis C associated with persistently normal ALT levels that support this observation. In particular, whether there is any progress in grading and staging of chronic hepatitis in these patients is not known.

This study was therefore designed to evaluate the natural history of a group of anti-Hepatitis C Virus-positive patients with persistently normal ALT levels during 7 years of prospective follow-up to provide further insights into the concept of disease progression. We found that patients with persistently normal ALT levels have chronic hepatitis whose grade of activity does not increase over 5 years of observation. This lends support to the concept that these patients may not benefit from interferon treatment.

Discussion:

Most patients infected with Hepatitis C Virus have different degrees of liver damage that can worsen and lead to liver cirrhosis in 20% of the cases, although subjects with normal liver histology despite ongoing Hepatitis C Virus viremia have been documented. However, the long-term natural history of the so-called asymptomatic carriers of Hepatitis C Virus is not clear. In general, although ALT levels do not relate to the entity of the liver damage, patients with persistently normal ALT levels have less severe disease. Supporting these data, Mathurin et al. (21) recently showed in a large cohort of patients that those with normal ALT had less severe fibrosis than those with increased ALT. Nevertheless, some reports show the presence of cirrhosis in such patients. Whether these patients should be treated with interferon is still subject to debate (14).

This study was designed to evaluate whether Hepatitis C Virus-infected subjects with persistently normal ALT levels have any progression of liver damage after 5 years of follow-up. This might be helpful in deciding whether these patients need to be treated with interferon. The prospective follow-up supports the concept that all Hepatitis C Virus-positive patients with persistently normal ALT levels have chronic hepatitis with slow progression, or no progression at all, to more severe liver disease (i.e., cirrhosis). The first consequence of this might be the inefficacy of interferon therapy in asymptomatic patients in favor of a wait-and-see approach. This is similar to data from a recent study of interferon treatment in asymptomatic patients14 concluding that such treatment is not effective in these patients. Nevertheless, interferon is suggested as a therapeutic choice for patients with mild disease and flaring ALT. The question is whether and when interferon should be a therapeutic option. In our study, no patients had increases in ALT values after the fourth year of follow-up. Possibly because of the accurate follow-up of such patients, we

selected a very strict group of subjects who really represent "asymptomatic" carriers of Hepatitis C Virus. Interestingly, patients with increases in ALT levels did not have the worst histological score, suggesting that ALT levels are not a valuable predictor of progression of disease. Most of these subjects( 6,7) treated with interferon did not benefit from the therapy, and the histological score 5 years after the end of interferon treatment showed progression to cirrhosis in 1 patient and mild progression of fibrosis in 2 patients. Only 1 patient responded to therapy; his histology improved from mild chronic hepatitis to minimal liver changes. A recent demonstration of a lower degree of fibrosis in patients with persistently normal ALT activity (21) supports the concept of very slow progression, if any, of liver disease in these subjects. However, whereas Mathurin et al. (21) evaluated progression of liver fibrosis over a virtual period of time of assumed years before biopsy, our data instead strongly demonstrate a lack of progression of disease activity in 2 liver biopsies performed several years apart in a prospective designed study.

    

The diversion of the 2 groups (asymptomatic and symptomatic), at the beginning of the study under the same name, may suggest that the pathological potential of Hepatitis C Virus is expressed only in a particular genetic background. The immune system of "asymptomatic Hepatitis C Virus carriers" might be able to satisfactorily react to the turnover of the quasi species, avoiding the escape mechanism.

The mean value of the apparent duration of the disease (determined only in a small sample and still under observation at the time of second biopsy) was about 10 years. This, added to the 5 years of follow-up, represents a long period of observation to draw conclusions on the natural history of the disease in these patients. Nevertheless, a longer follow-up might be needed.

The indifferent Hepatitis C Virus genotype distribution together with the lack of association of any particular Hepatitis C Virus genotype, with a more or less pronounced disease progression, confirms our and other investigators' observations; and seems to rule out the possibility that the state of asymptomatic carriers of Hepatitis C Virus might be mainly determined by a more or less aggressive Hepatitis C Virus genotype.

Through initial screening of anti-Hepatitis C Virus-positive patients, we recognized 2 patients who were Hepatitis C Virus RNA negative and who had normal liver histology. These patients never showed positivity for Hepatitis C Virus RNA. They might have recovered from the acute disease showing a permanent immunity (anti-Hepatitis C Virus positive). One patient who was persistently positive for Hepatitis C Virus RNA also had no signs of liver disease at biopsy, thus confirming that true "healthy carriers" of Hepatitis C Virus may exist. In conclusion, this study suggests that the majority of asymptomatic carriers of anti-Hepatitis C Virus have histological features of very mild chronic hepatitis. In these patients with more than 5 years of observation, the disease does not worsen, supporting the concept that the natural history of chronic hepatitis in this group of subjects is characterized by very slow or no progression at all to more severe grades of evolution. This supports the useless approach with interferon therapy in these patients. Data also show that anti-Hepatitis C Virus carriers, along with subjects with chronic hepatitis and Hepatitis C Virus healthy carriers, may represent subjects who healed after Hepatitis C Virus infection. A very strict follow-up with frequent ALT level determinations is suggested in these patients to recognize subjects only apparently "asymptomatic" for making appropriate therapeutic decisions.

(6) Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L and Resta S Hepatology, Vol 26, 1393-1398

This study was aimed to evaluate demographic, clinical, histological, and virological characteristics of 46 hepatitis C virus (Hepatitis C Virus) carriers with persistently normal alanine transaminase (ALT) levels and to compare the results with those obtained in a group of 52 Hepatitis C Virus-RNA- positive patients with elevated ALT levels. Subjects with normal ALT were more often females (P < .001), were more likely to be asymptomatic (P < .001), and have a lower incidence of risk factors for Hepatitis C Virus transmission (P < .01). All patients with normal ALT had significant histological liver damage. The mean grading and staging did not differ between patients withnormal and those with raised ALT concentrations. Moderate to severe hepatitis was more frequently found among subjects with normal than with elevated ALT. Hepatitis C Virus genotype 2a was far more common in subjects with normal (43%) than with abnormal ALT levels (6%; P < .002), genotype 1b being more frequent in these latter (50% vs. 17%; P < .001). Patients with normal ALT levels had similar serum Hepatitis C Virus-RNA titers than subjects with raised ALT. Neither Hepatitis C Virus genotype distribution nor viral load correlated with the severity of liver damage. We conclude that significant liver disease may occur irrespective of clinical symptoms, ALT levels, Hepatitis C Virus genotypes, and viral load.

(14) Interferon Alfa Treatment of Hepatitis C Virus RNA Carriers With Persistently Normal Transaminase Levels: A Pilot Randomized Controlled Study

Sangiovanni1 A, Morales R, Spinzi GC, Rumi MG, Casiraghi A, Ceriani R, Colombo E, Fossati M, Prada A, Tavani E, and Minoli G HEPATOLOGY, March 1998, p. 853-856, Vol. 27, No. 3

Most patients with serum hepatitis C virus (Hepatitis C Virus) RNA and persistently normal alanine transaminase (ALT) levels show histological features of mild to moderately active chronic hepatitis. Some cirrhosis has also been reported. To assess whether interferon (IFN) treatment led to long-term Hepatitis C Virus suppression in these patients, 31 previously untreated patients (15 men, 16 women; mean age, 44 years) with serum Hepatitis C Virus RNA, persistently normal ALT levels on at least four consecutive occasions 2 months apart, and histological features of chronic hepatitis (21 mild activity, 10 moderate activity) were randomized to receive IFN--2a, 3 MU three times a week for 6 months (n = 16), or no treatment (n = 15). All patients were followed up for at least 6 months after treatment ended. Hepatitis C Virus RNA was tested by nested reverse-transcription polymerase chain reaction (RT-PCR) using 5'-untranslated region complementary primers, quantified by branched-DNA assay, and typed by nested RT-PCR testing for the Hepatitis C Virus core region. Treated and untreated patients had similar epidemiological, virological, and histological characteristics. At the end of treatment, serum Hepatitis C Virus RNA was still detected in 15 patients (94%) and 14 controls (93%). ALT levels flared up in 10 patients receiving IFN (62%) and in 1 control (62% vs. 7%; P < .005, 2 test). In conclusion, 6 months' treatment with IFN--2a did not eradicate Hepatitis C Virus RNA from serum in carriers with persistently normal ALT levels but caused ALT flare-ups in two thirds of them. Until more is known about the natural history of Hepatitis C Virus RNA carriers with normal ALT levels, these patients should not be treated with IFN.

(21) Slow Progression Rate of Fibrosis in Hepatitis C Virus Patients With Persistently Normal Alanine Transaminase Activity

Mathurin P, Moussalli1 J, Cadranel JF, Thibault V, Charlotte F, Dumouche P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, and Poynard T HEPATOLOGY, March 1998, p. 868-872, Vol. 27, No. 3

In hepatitis C virus (Hepatitis C Virus) patients with persistently normal alanine transaminase (ALT), the progression rate of fibrosis is unknown. The aims of this study were: 1) to compare Hepatitis C Virus patients with normal ALT (group I) with Hepatitis C Virus patients with elevated ALT (group II) matched on independent factors associated with fibrosis; and 2) to assess the progression rate of fibrosis. One hundred two Hepatitis C Virus patients were included in each group. Histological lesions were staged using the METAVIR score. We defined fibrosis progression per year as the ratio of the fibrosis stage in METAVIR units to the duration of infection. In group I, ALT values were normal, and lower than in group II (25 vs. 127 IU/L; P < .0001). Hepatitis C Virus RNA was present less frequently in group I (66% vs. 97%; P < .0001). There were no significant differences for viremia and genotypes. Histological activities were lower in group I (0.6 vs. 1.38; P < .0001). The stage of fibrosis was lower in group I (0.95 vs. 1.8; P < .001). The median progression rate of fibrosis was lower in group I (0.05 vs. 0.13; P < .001). In group I, after exclusion of negative Hepatitis C Virus-RNA patients, the median progression rate of positives remained lower (0.05 vs. 0.13; P < .001). In group I, all cirrhotic patients (n = 3) were heavy drinkers. Hepatitis C Virus patients with normal ALT showed weaker histological activity and lower fibrosis scores, and the progression rate of fibrosis was twice as slow as in Hepatitis C Virus patients with elevated ALT. In these patients, severe fibrosis was associated with high alcohol consumption.